Role of EGFR as a prognostic factor for survival in head and neck cancer: A meta-analysis

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2285-2295

  Keren, Shen ^a   Shoude, Zhang ^b   Lu, Zhao ^b   Beibei, Yang ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

EGFR; HNSCC; Meta analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; META ANALYSIS; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899118545     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1303-0     Document Type: Article

References (73)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29. doi: 10.3322/caac.20138.
2. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143-54. doi: 10.1056/NEJMra0707975.
3. Kundu SK, Nestor M. Targeted therapy in head and neck cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2012;33(3):707-21. doi: 10.1007/s13277-012-0350-2.
4. Zhang S, Chen J, Jiang H, Ma H, Yang B. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. Eur J Clin Pharmacol. 2012;68(5):561-9. doi: 10.1007/s00228-011- 1194-1.
5. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9-22. doi: 10.1038/nrc2982.
6. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology. 2009;77(6):400-10. doi: 10.1159/000279388.
7. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579-84.
8. Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013. doi: 10.1007/s40265-013-0025-3.
9. Chan AT, Felip E. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2009;20 Suppl 4:123-5. doi: 10.1093/annonc/mdp150.
10. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-34.
11. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18(4):705-19.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101.
14. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-63.
15. Issing WJ, Liebich C, Wustrow TP, Ullrich A. Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer. Anticancer Res. 1996;16(1):283-8.
16. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824-32.
17. Maurizi M, Ferrandina G, Almadori G, Scambia G, Cadoni G, D'Agostino G, et al. Prognostic significance of methyl-p-hydroxy-phenyllactate-esterase activity in laryngeal squamous cell carcinoma. Br J Cancer. 1998;77(8):1253-9.
18. Maiorano E, Favia G, Maisonneuve P, Viale G. Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. J Pathol. 1998;185(2):167-74. doi: 10.1002/(SICI)1096- 9896(199806)185:2<167::AID-PATH70>3.0.CO;2-E.
19. Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer. 1999;79(11-12):1864-9. doi: 10.1038/sj.bjc.6690297.
20. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5(12):4164-74.
21. Smith BD, Smith GL, Carter D, DiGiovanna MP, Kasowitz KM, Sasaki CT, et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127(7):780-5.
22. Aebersold DM, Froehlich SC, Jonczy M, Beer KT, Laissue J, Greiner RH, et al. Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2002;63(3):275-83.
23. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350-6.
24. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer. 2003;89(4):681-6. doi: 10.1038/sj.bjc. 6601171.
25. Pivot X, Magne N, Guardiola E, Poissonnet G, Dassonville O, Francoual M, et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol. 2005;41(3):320-7. doi: 10.1016/j.oraloncology.2004.09.011.
26. Shiraki M, Odajima T, Ikeda T, Sasaki A, Satoh M, Yamaguchi A, et al. Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancer. Mod Pathol Off J U S Can Acad Pathol Inc. 2005;18(11):1482-9. doi: 10.1038/modpathol. 3800455.
27. Kong A, Leboucher P, Leek R, Calleja V, Winter S, Harris A, et al. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res. 2006;66(5):2834-43. doi: 10.1158/0008-5472.CAN-05-2994.
28. Smid EJ, Stoter TR, Bloemena E, Lafleur MV, Leemans CR, van der Waal I, et al. The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65(5):1323-9. doi: 10.1016/j.ijrobp.2006.03.011.
29. Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong D, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol. 2007;43(2):193-8. doi: 10.1016/j.oraloncology.2006.02.009.
30. Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007;120(8):1731-8. doi: 10.1002/ijc.22355.
31. Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A. Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis. 2007;13(3):285-90. doi: 10.1111/j.1601-0825. 2006.01280.x.
32. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128-37. doi: 10.1200/JCO.2007.12.7662.
33. Jiang H, Yang BB. p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. Acta Otolaryngol. 2009;129(1):101-7. doi: 10.1080/00016480802054185.
34. Ryott M, Wangsa D, Heselmeyer-Haddad K, Lindholm J, Elmberger G, Auer G, et al. EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. Eur J Cancer. 2009;45(9):1700-8. doi: 10.1016/j.ejca.2009.02.027.
35. Shah NG, Trivedi TI, Tankshali RA, Goswami JV, Jetly DH, Shukla SN, et al. Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck. 2009;31(12):1544-56. doi: 10.1002/hed.21126.
36. Farhadieh RD, Salardini A, Rees CG, Russell PJ, Yang JL, Smee R. Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. Ann Surg Oncol. 2009;16(10):2888-94. doi: 10.1245/s10434-009-0649-4.
37. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27(36):6213-21. doi: 10.1200/JCO.2009.23.1670.
38. Al-Swiahb JN, Huang CC, Fang FM, Chuang HC, Huang HY, Luo SD, et al. Prognostic impact of p16, p53, epidermal growth factor receptor, and human papillomavirus in oropharyngeal cancer in a betel nut-chewing area. Arch Otolaryngol Head Neck Surg. 2010;136(5):502-8. doi: 10.1001/archoto.2010.47.
39. Hong A, Dobbins T, Lee CS, Jones D, Jackson E, Clark J, et al. Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur J Cancer. 2010;46(11):2088-96. doi: 10.1016/j.ejca.2010.04.016.
40. Numico G, Russi EG, Colantonio I, Lantermo RA, Silvestris N, Vitiello R, et al. EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res. 2010;30(2):671-6.
41. Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, et al. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(9):2947-54. doi: 10.1158/1078-0432.CCR-10-2040.
42. Young RJ, Rischin D, Fisher R, McArthur GA, Fox SB, Peters LJ, et al. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1230-7. doi: 10.1158/1055-9965.EPI-10-1262.
43. Nakata Y, Uzawa N, Takahashi K, Sumino J, Michikawa C, Sato H, et al. EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. Eur J Cancer. 2011;47(15):2364-72. doi: 10.1016/j.ejca.2011.07.006.
44. Trivedi TI, Tankshali RA, Goswami JV, Shukla SN, Shah PM, Shah NG. Identification of site-specific prognostic biomarkers in patients with oral squamous cell carcinoma. Neoplasma. 2011;58(3):217-26.
45. Lindquist D, Ahrlund-Richter A, Tarjan M, Tot T, Dalianis T. Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res. 2012;32(1):153-61.
46. Nichols AC, Whelan F, Basmaji J, Dhaliwal S, Dowthwaite S, Chapeskie C, et al. Ki-67 expression predicts radiotherapy failure in early glottic cancer. J Otolaryngol Head Neck Surg Le Journal d'oto-rhino-laryngologie et de Chirurgie Cervico-Faciale. 2012;41(2):124-30.
47. Won HS, Jung CK, Chun SH, Kang JH, Kim YS, Sun DI, et al. Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma. Oral Oncol. 2012;48(10):985-90. doi: 10.1016/j.oraloncology.2012.04.013.
48. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Warnakulasuriya S, Forteza J, Fraga M. Combined cytoplasmic and membranous EGFR and p53 overexpression is a poor prognostic marker in early stage oral squamous cell carcinoma. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2012;41(7):559-67. doi: 10.1111/j.1600-0714.2012.01142.x.
49. Rahimi AS, Wilson DD, Saylor DK, Stelow EB, Thomas CY, Reibel JF, et al. p16, Cyclin D1, and HIF-1alpha predict outcomes of patients with oropharyngeal squamous cell carcinoma treated with definitive intensity-modulated radiation therapy. Int J Otolaryngol. 2012;2012:685951. doi: 10.1155/2012/685951.
50. Lundberg M, Leivo I, Saarilahti K, Makitie AA, Mattila PS. Transforming growth factor beta 1 genotype and p16 as prognostic factors in head and neck squamous cell carcinoma. Acta Otolaryngol. 2012;132(9):1006-12. doi: 10.3109/00016489.2012.678944.
51. Huang SF, Cheng SD, Chien HT, Liao CT, Chen IH, Wang HM, et al. Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. Oral Oncol. 2012;48(1):67-72. doi: 10.1016/j.oraloncology.2011.06.511.
52. Greene FL, Page DL, Fleming, et al. AJCC cancer staging mannual. 6th ed. New York: Springer-Verlag; 2002.
53. Administration USFaD. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm278894.htm.
54. Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 2003;63(6):1179-82.
55. Takes RP, Baatenburg de Jong RJ, Schuuring E, Litvinov SV, Hermans J, Van Krieken JH. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res. 1998;18(6B):4793-800.
56. Berrino F, Gatta G. Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. EUROCARE Working Group. Eur J Cancer. 1998;34(14 Spec No):2154-61.
57. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114(5):806-16. doi: 10.1002/ijc.20740.
58. Smith RR, Caulk R, Frazell E, Holinger PH, MacComb WS, Russell WO, et al. Revision of the clinical staging system for cancer of the larynx. Cancer. 1973;31(1):72-80.
59. Stambuk HE, Karimi S, Lee N, Patel SG. Oral cavity and oropharynx tumors. Radiol Clin N Am. 2007;45(1):1-20. doi: 10.1016/j.rcl.2006.10.010.
60. Udeabor SE, Rana M, Wegener G, Gellrich NC, Eckardt AM. Squamous cell carcinoma of the oral cavity and the oropharynx in patients less than 40 years of age: a 20-year analysis. Head Neck Oncol. 2012;4:28. doi: 10.1186/1758-3284-4-28.
61. Genden EM, Ferlito A, Bradley PJ, Rinaldo A, Scully C. Neck disease and distant metastases. Oral Oncol. 2003;39(3):207-12.
62. Severino P, Alvares AM, Michaluart Jr P, Okamoto OK, Nunes FD, Moreira-Filho CA, et al. Global gene expression profiling of oral cavity cancers suggests molecular heterogeneity within anatomic subsites. BMC Res Notes. 2008;1:113. doi: 10.1186/1756-0500-1-113.
63. Idikio HA. Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. Int J Clin Exp Pathol. 2009;3(2):169-76.
64. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem Off J Histochem Soc. 2004;52(7):893-901. doi: 10.1369/jhc.3A6195.2004.
65. Gill S, Sargent D. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist. 2006;11(6):624-9. doi: 10.1634/theoncologist.11-6-624.
66. Zandberg DP, Bhargava R, Badin S, Cullen KJ. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 2013;63(1):57-81. doi: 10.3322/caac.21167.
67. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. doi: 10.1056/NEJMoa0912217.
68. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13 Suppl 2:19-21. doi: 10.1634/theoncologist.13-S2-19.
69. Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol. 2012;48(11):1085-9. doi: 10.1016/j.oraloncology.2012.06.016.
70. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(23):8288-94. doi: 10.1158/1078-0432.CCR-05-0827.
71. Markovic A, Chung CH. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2012;12(9):1149-59. doi: 10.1586/era.12.91.
72. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ. 2001;323(7306):224-8.
73. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using «optimal» cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86(11):829-35.